Posted by Michael Wonder on 31 Aug 2018
Alnylam receives approval of Onpattro (patisiran) in Europe
30 August 2018 - First ever RNAi therapeutic approved in the European Union.
Alnylam Pharmaceuticals announced today that the European Commission has granted marketing authorization for Onpattro (patisiran) for the treatment of hereditary transthyretin-mediated (hATTR) amyloidosis in adults with stage 1 or stage 2 polyneuropathy.
Onpattro is based on Nobel Prize winning science and is the first-ever RNA interference therapeutic to be approved in the European Union.
